Indication
Childhood Ependymoma
7 clinical trials
11 products
3 drugs
Clinical trial
A Safety and Preliminary Efficacy Trial of Pembrolizumab (MK-3475) in Children With Recurrent, Progressive or Refractory Diffuse Intrinsic Pontine Glioma (DIPG), Non-Brainstem High-Grade Gliomas (NB-HGG), Ependymoma, Medulloblastoma or Hypermutated Brain TumorsStatus: Recruiting, Estimated PCD: 2026-12-31
Product
PembrolizumabClinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle GenesStatus: Active (not recruiting), Estimated PCD: 2023-03-31
Product
PalbociclibClinical trial
Pilot Study of High-Dose Chemotherapy With Busulfan, Melphalan, and Topotecan Followed by Autologous Hematopoietic Stem Cell Transplant in Advanced Stage and Recurrent TumorsStatus: Active (not recruiting), Estimated PCD: 2013-01-19
Product
melphalanDrug
busulfanClinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- A Phase 2 Subprotocol of Olaparib in Patients With Tumors Harboring Defects in DNA Damage Repair GenesStatus: Active (not recruiting), Estimated PCD: 2023-03-31
Product
OlaparibProduct
TopotecanDrug
FilgrastimClinical trial
An International Clinical Program for the Diagnosis and Treatment of Children, Adolescents and Young Adults With EpendymomaStatus: Recruiting, Estimated PCD: 2028-06-01
Product
16 weeks of VEC + CDDPProduct
VEC + HD-MTXProduct
ValproateProduct
VECDrug
DocetaxelClinical trial
Phase II Study of Everolimus (RAD001, Afinitor®) for Children With Recurrent or Progressive EpendymomaStatus: Completed, Estimated PCD: 2023-07-14
Product
EverolimusClinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Erdafitinib in Patients With Tumors Harboring FGFR1/2/3/4 AlterationsStatus: Active (not recruiting), Estimated PCD: 2023-09-30
Product
Erdafitinib